Functional and binding characteristics of long-acting beta(2)-agonists in lung and heart

被引:38
作者
Roux, FJ
Grandordy, B
Douglas, JS
机构
[1] YALE UNIV,SCH MED,NEW HAVEN,CT
[2] CIBA GEIGY AG,RES & DEV,CH-4002 BASEL,SWITZERLAND
关键词
D O I
10.1164/ajrccm.153.5.8630591
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Salmeterol and formoterol, two new long-acting beta(2)-agonists were equipotent (values of negative log molar concentration eliciting half-maximal effect [pD(2)] 9.2 +/- 0.03 and 8.9 +/- 0.03, respectively) in relaxing maximally contracted guinea pig tracheal spirals (histamine, 100 mu M). Both agonists were 10 times more potent than L-isoproterenol and fenoterol and 100 times more potent than albuterol, L-Isoproterenol and fenoterol induced > 90% relaxation (percentage of maximal aminophylline relaxation). Formoterol and albuterol were equally efficacious. Formoterol was more efficacious (86 +/- 5%) than salmeterol (62 +/- 3%) or soterenol (59 +/- 3%). In minimally contracted tissues (10 mu M histamine), agonist potencies increased 10-fold and relaxation was complete. In [I-125]iodocyanopindolol-labeled bronchial membranes, formoterol and salmeterol induced high-affinity states of the beta(2)-receptor (pK(h) 9.6 +/- 0.4 and 10.4 +/- 0.7, respectively), the former inducing a higher percentage (57 +/- 6 versus 28 +/- 4, p < 0.05). Only low-affinity binding (pK(l)) was observed when guanine nucleotide was present. pD(2) values were similar to pK(h) values and relative efficacies significantly correlated with percentage of pK(h) sites. Formoterol and salmeterol were highly selective for the Pt versus beta(1)-subtype (pK(l) values were 8.2 +/- 0.09 and 6.25 +/- 0.06 and 8.3 +/- 0.04 and 5.7 +/- 0.04, respectively). Albuterol (5.83 +/- 0.06 and 4.71 +/- 0.16) and fenoterol (6.33 +/- 0.07 and 5.67 +/- 0.05) were less selective. These results can explain the potencies and efficacies of salmeterol and formoterol in humans.
引用
收藏
页码:1489 / 1495
页数:7
相关论文
共 31 条
[1]   WHY ARE LONG-ACTING BETA-ADRENOCEPTOR AGONISTS LONG-ACTING [J].
ANDERSON, GP ;
LINDEN, A ;
RABE, KF .
EUROPEAN RESPIRATORY JOURNAL, 1994, 7 (03) :569-578
[2]   SALMETEROL, A NOVEL, LONG-ACTING BETA-2-ADRENOCEPTOR AGONIST - CHARACTERIZATION OF PHARMACOLOGICAL ACTIVITY INVITRO AND INVIVO [J].
BALL, DI ;
BRITTAIN, RT ;
COLEMAN, RA ;
DENYER, LH ;
JACK, D ;
JOHNSON, M ;
LUNTS, LHC ;
NIALS, AT ;
SHELDRICK, KE ;
SKIDMORE, IF .
BRITISH JOURNAL OF PHARMACOLOGY, 1991, 104 (03) :665-671
[3]  
BRITTAIN RT, 1981, RESPIRATORY PHARM, P613
[4]  
BROWN MJ, 1985, AM J CARDIOL, V56, pD3, DOI 10.1016/0002-9149(85)91107-5
[5]  
BUCKNER CK, 1975, J PHARMACOL EXP THER, V194, P565
[6]  
CERIONE RA, 1984, J BIOL CHEM, V259, P9979
[7]   FORMOTEROL - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC POTENTIAL IN REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE [J].
FAULDS, D ;
HOLLINGSHEAD, LM ;
GOA, KL .
DRUGS, 1991, 42 (01) :115-137
[8]   SALMETEROL IN NOCTURNAL ASTHMA - A DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF A LONG-ACTING INHALED BETA-2 AGONIST [J].
FITZPATRICK, MF ;
MACKAY, T ;
DRIVER, H ;
DOUGLAS, NJ .
BRITISH MEDICAL JOURNAL, 1990, 301 (6765) :1365-1368
[9]  
GRANDORDY BM, 1986, J PHARMACOL EXP THER, V238, P273
[10]   MODULATION OF AIRWAY SMOOTH-MUSCLE BETA-ADRENOCEPTOR FUNCTION BY A MUSCARINIC AGONIST [J].
GRANDORDY, BM ;
MAK, JCW ;
BARNES, PJ .
LIFE SCIENCES, 1994, 54 (03) :185-191